Table 1.
Baseline characteristics
| Characteristics | Combination group (n = 22) | Chemotherapy group (n = 36) | P value |
|---|---|---|---|
| Median age, years (range) | 56.0 (34–73) | 54.0 (30–77) | 0.573 |
| Sex, n (%) | 0.955 | ||
| Male | 13 (59.1%) | 21 (58.3%) | |
| Female | 9 (40.9%) | 15 (41.7%) | |
| Alcohol history, n (%) | 0.967 | ||
| Former or current | 6 (27.3%) | 10 (27.8%) | |
| Never or unknown | 16 (72.7%) | 26 (72.2%) | |
| Pancreatic tumor location, n (%) | 0.484 | ||
| Head | 12 (54.5%) | 23 (63.0%) | |
| Body or tail | 10 (45.5%) | 13 (36.1%) | |
| Smoking history, n (%) | 0.673 | ||
| Former or current | 5 (22.7%) | 10 (27.8%) | |
| Never or unknown | 17 (77.3%) | 26 (72.2%) | |
| ECOG performance status, n (%) | 0.261 | ||
| 0–2 | 21 (95.5%) | 31 (86.1%) | |
| > 2 | 1 (4.5%) | 5 (13.9%) | |
| Previous surgery, n (%) | 0.092 | ||
| Yes | 8 (36.4%) | 6 (16.7%) | |
| No | 14 (63.6%) | 30 (83.3%) | |
| Number of prior lines of treatment for metastatic disease, n (%) | 0.016 | ||
| 0 | 17 (72.3%) | 35 (97.2%) | |
| ≥ 1 | 5 (22.7%) | 1 (2.8%) | |
| Site of metastases, n (%) | |||
| Liver | 20 (90.9%) | 29 (80.6%) | 0.295 |
| Lymph node | 20 (90.9%) | 31 (86.1%) | 0.590 |
| Lung | 5 (22.7%) | 4 (11.1%) | 0.240 |
| Peritoneal | 4 (18.2%) | 6 (16.7%) | 0.883 |
| Other | 5 (22.7%) | 8 (22.2%) | 0.965 |
| Number of metastases | 0.484 | ||
| 0–2 | 12 (54.5%) | 23 (63.9%) | |
| ≥ 3 | 10 (45.5%) | 13 (36.1%) |
ECOG Eastern Cooperative Oncology Group